Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Intellia Therapeutics (NTLA) over the last 5 years, with Sep 2025 value amounting to $110.2 million.

  • Intellia Therapeutics' Shares Outstanding (Diluted Average) rose 9.09% to $110.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.2 million, marking a year-over-year increase of 9.09%. This contributed to the annual value of $98.8 million for FY2024, which is 11.35% up from last year.
  • Per Intellia Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $110.2 million for Q3 2025, which was up 6.22% from $103.7 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $110.2 million for Q3 2025, and its period low was $68.2 million during Q2 2021.
  • In the last 3 years, Intellia Therapeutics' Shares Outstanding (Diluted Average) had a median value of $97.0 million in 2024 and averaged $96.6 million.
  • Data for Intellia Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY increased of 26.63% (in 2021) over the last 5 years.
  • Intellia Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $70.9 million in 2021, then increased by 8.57% to $77.0 million in 2022, then increased by 15.33% to $88.8 million in 2023, then rose by 11.35% to $98.8 million in 2024, then increased by 9.09% to $110.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $110.2 million in Q3 2025, compared to $103.7 million in Q2 2025 and $103.5 million in Q1 2025.